The verdict
Our read at a glance.
Whether cerebrolysin's large but mixed evidence in stroke, dementia, and brain injury supports the broad brain-recovery and cognitive claims made for it.
- The signal
- Many trials and systematic reviews have studied cerebrolysin in acute stroke, vascular and Alzheimer dementia, and traumatic brain injury. Results are mixed: some reviews suggest possible benefit on certain measures, while others find no clear effect or note quality and bias concerns. It is not approved in the US.
- The unknown
- Whether cerebrolysin produces meaningful, reliable benefit in any specific condition once trial quality is accounted for, and how a biological mixture's identity and consistency affect results.
- Our read
- A widely used but unevenly supported brain treatment, not a proven cognitive enhancer. Cerebrolysin has a large evidence base, but it is mixed and its strongest use is in specific conditions and countries, so broad brain-recovery claims should be read cautiously.
The mechanism
How it works.
Cerebrolysin is a liquid mixture of low-molecular-weight peptides and free amino acids made by enzymatically breaking down pig brain tissue, so it is a defined biological preparation rather than a single molecule. The proposed mechanism is that some of these peptide fragments mimic the body's own neurotrophic factors, signals that help nerve cells survive, repair, and form connections, which is the rationale for giving it after stroke or brain injury. Because it is a complex mixture and not a purified drug, exactly which components act and how they work in the human brain has never been pinned down, and its clinical evidence stays mixed.
Safety & regulatory boundary
The consequential part.
Cerebrolysin is not approved in the US, and its approval and use are jurisdiction-specific. It is a biological mixture from animal tissue, so product identity and consistency matter, and it is given under medical supervision where used. The mixed evidence does not establish broad brain-recovery or cognitive-enhancement claims, and products outside regulated channels are of uncertain identity.
What's next
What we're watching.
Higher-quality independent trials, updated systematic reviews, and regulatory status in different regions.
Context
Why this is discussed.
Cerebrolysin is widely used in some countries for brain conditions and is discussed internationally as a brain-recovery and nootropic treatment, despite not being approved in places like the US.
The evidence base
20 cited references.
Registered trials8
ClinicalTrials.gov · PHASE4 · RECRUITING · 2023-06-01
ClinicalTrials.gov · PHASE3 · COMPLETED · 2023-09-01
ClinicalTrials.gov · PHASE1/PHASE2 · RECRUITING · 2023-08-24
ClinicalTrials.gov · NA · RECRUITING · 2025-06-13
ClinicalTrials.gov · PHASE4 · NOT_YET_RECRUITING · 2025-10-01
ClinicalTrials.gov · PHASE4 · RECRUITING · 2025-03-12
ClinicalTrials.gov · COMPLETED · 2018-04-24
ClinicalTrials.gov · PHASE2 · ACTIVE_NOT_RECRUITING · 2023-11-29
Indexed literature (PubMed)12
Cook AM et al. · CNS Drugs · 2025
Jarosz K et al. · Brain Sci · 2023
Gauthier S et al. · Dement Geriatr Cogn Disord · 2015
Bornstein NM et al. · Neurol Sci · 2018
Kojder K et al. · J Clin Med · 2023
Guekht A et al. · Neurol Sci · 2017
Masserini F et al. · Alzheimers Dement · 2025
Strilciuc S et al. · Pharmaceuticals (Basel) · 2021
Zhang D et al. · Biomed Res Int · 2017
Yanık T et al. · Turk J Phys Med Rehabil · 2024
Bischoff S et al. · Curr Allergy Asthma Rep · 2024
Ziganshina LE et al. · Cochrane Database Syst Rev · 2023
Keep reading